Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort.
Fiche du document
2014
- doi: 10.1186/1475-2875-13-197
- issn: 1475-2875
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/1475-2875-13-197
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/24884890
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1475-2875
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_BB36626BAE4A2
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
GestationCiter ce document
D. Mosha et al., « Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. », Serveur académique Lausannois, ID : 10.1186/1475-2875-13-197
Métriques
Partage / Export
Résumé
BACKGROUND: There is limited data available regarding safety profile of artemisinins in early pregnancy. They are, therefore, not recommended by WHO as a first-line treatment for malaria in first trimester due to associated embryo-foetal toxicity in animal studies. The study assessed birth outcome among pregnant women inadvertently exposed to artemether-lumefantrine (AL) during first trimester in comparison to those of women exposed to other anti-malarial drugs or no drug at all during the same period of pregnancy. METHODS: Pregnant women with gestational age